Search results for: 'research-area cell-cycle'
Items 1-10 of 583
- AZD7762Catalog No. :A5919Checkpoint kinase inhibitor,ATP competitiveAZD7762 is a novel ATP competitive inhibitor of checkpoint kinases. Chk family checkpoint kinases include Chk1 and Chk2. They are activated in response to DNA damage and phosphorylate CDC25A, CDC25C protein phosphatases, which delay cell cycle progression. Therefore, Chk activation initiates cell cycle checkpoint, causes cell cycle arrest, and allows DNA repair.
- R547Catalog No. :A8642CDK1/2/4 inhibitor,ATP-competitive
R547 is a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases with a Ki of median 2 nM for CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1((Ki=0.001,0.003,and 0.001 μM for CDK1,CDK2, and CDK4,respectively).
- MK-8776 (SCH-900776)Catalog No. :A8477Chk1 inhibitor,potent and selective
SCH 900776 is a potent and functionally selective inhibitor targeting cell cycle checkpoint kinase 1 (Chk1) (IC50 = 3 nM), Cdk2 (IC50 = 0.16 µM), and Chk2 (IC50 = 1.5 µM). Chk1 is an essential serine/threonine kinase which responds to DNA damage and stalls DNA replication, Chk1 is also essential for maintenance of replication fork viability during exposure to DNA antimetabolites. SCH 900776 is a weak inhibitor of CDK2.
- BS-181 HClCatalog No. :A5700CDK7 inhibitor,highly selective
Normal progression through the cell cycle requires the sequential action of cyclin-dependent kinases CDK1, CDK2, CDK4, and CDK6. Direct or indirect deregulation of CDK activity is a feature of almost all cancers and has led to the development of CDK inhibitors as anticancer agents.
- Roscovitine (Seliciclib,CYC202)Catalog No. :A1723CDK inhibitor,potent and selective
Roscovitine, also known as seliciclib or CYC202, is a selective cyclin-dependent kinases (cdk), which are essential cell cycle regulators frequently involved in the deregulation of human tumors, inhibitor that potently inhibits cdc2 (cdc2/cyclin B), cdk2 (cdk2/cyclin A and cdk2/cyclin E) and cdk5 (cdk5/p35) with half maximal inhibition concentration IC50 of 0.65 μM, 0.7 μM, 0.7 μM and 0.16 μM respectively .
- DocetaxelCatalog No. :A4394Microtubulin disassembly inhibitor
Docetaxel, a new taxoid family member originally derived from the needles of the European Yew tree Taxus baccata, is a potent chemotherapeutic agent that acts as a spindle poison to inhibit microtubule dynamics and cell cycle arrest through promoting microtublin assembly and stabilizing the polymers against depolymerization.
- AZD-5438Catalog No. :A8326Potent CDK1/2/9 inhibitor
AZD5438 is a potent small molecule inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 with half maximal inhibitory concentration IC50 of 16 nmol/L, 6 nmol/L and 20 nmol/L respectively. AZD5438 has also been found to potently inhibit the human cyclin E/CDK2 complex, the cyclin B1/CDK1 complex and the cyclin A/CDK2 complex with IC50 of 0.006 μM, 0.016 μM and 0.045 μM respectively. In previous studies, AZD5438 has exhibited significant anti-proliferative activity in a few human tumor cell lines with IC50 ranging from 0.2 μmol/L to 1.7 μmol/L, in which the phosphorylation of a few proteins, including CDK substrates pRb, nucleolin, protein phosphatase 1a and RNA polymerase II COOH-terminal domain, and cell cycling at G2-M, S and G1 phases were inhibited.
- Rigosertib sodium saltCatalog No. :A1404Plk1 inhibitor
Rigosertib (ON-01910) is a potent, specific PLK1 inhibitor with IC50 value of 9nM. Rigosertib strongly inhibited the proliferation of cancer cell lines, with observed IC50 values in the nanomolar range for both HeLa (115 nM) and C33A (45 nM) cells. In contrast, rigosertib had a minimal effect on normal cell lines, BJ and Ect1/E6E7 (IC50 > 0.1 mM)
- Paclitaxel (Taxol)Catalog No. :A4393Antineoplastic agent
Paclitaxel is a novel antineoplastic agent, which was discovered in a screen of extracts of thousands of plants and natural products for antineoplastic activity by a National Cancer Institute program.
- Epidermal Growth Factor Receptor Peptide (985-996)Catalog No. :A1021EGFR Peptide (985-996)
EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, includingepidermal growth factor and transforming growth factor α. EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity.